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Prolonged glucocorticoid therapy can lead to loss of bone mineral density (BMD) and 
higher risk of fracture. Fortunately this can be prevented or reduced if preventive 
measures are started early. Calcitriol (1,25-dihydroxyvitamin D3) and calcium 
supplementation is a rational therapy for minimising bone loss but has not been widely 
used locally. 
Objective: 
Our primary objective was to study the effect of calcitriol and calcium carbonate 
supplementation in the prevention of glucocorticoid-induced osteoporosis in our local 
systemic lupus erythematosus (SLE) patients. Our secondary objectives were to identify 
factors, which influenced the rate of bone loss in our SLE patients and also to see the 
effect of calcitriol and calcium carbonate on glucocorticoid-induced bone loss in the 
subgroup of patients with nonnal or reduced baseline BMD 
Methods: 
Sixty-nine SLE patients who were on long term glucocorticoid therapy were randomly 
assigned to receive either oral ca1citriol 0.25 ).lg BD or calcium carbonate 1.25 gm BD 
for one year. BMD was measured every six months for a year by the same dual X-ray 
absorptiometry (DXA). There were no significant differences between groups at entry 
with respect to demographics and risk factors for osteoporosis. Analysis was done to see 
the effect of supplementation on the BMD of the spine and femur. Further sub-analysis 
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was made to see the effect of supplementation on BMD of patients with normal bone 
density or osteopenia at entry. 
Results: 
Calcitriol was more effective than calcium in preventing bone loss from the spine. Mean 
percentage change at 6 month for calcitriol and calcium were 2.16% and -0.55 % 
(p=0.05) respectively. While mean of change of BMD at one year for calcitriol and 
calcium were 0.52% and -0.32% respectively. Calcitriol also prevent bone loss from the 
femur in the first 6 months of the study (mean percentage change of 0.630/0) but to a 
lesser degree than that in the spine. Calcium was unable to provide any protection 
against bone loss in the spine or femur 
Those patients with osteopenic at baseline benefited most from calcitriol and calcium 
supplementation. When given calcitriol, their mean percentage increase in BMD of the 
spine were 3.62% at 6 month and 1.68% at one year. Those on calcium also showed an 
increase in BMD of 0.77% and 1.66% respectively. 
Patients with normal baseline bone density showed an improvement only at the spine at 
6 month (percentage increase of 1.12%) when given calcitriol supplementation. 
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Conclusion: 
Calcitriol supplementation was more effective in preventing glucocorticoid-induced 
bone loss than calcium supplementation. Calcitriol with calcium supplementation 
offered protection against glucocorticoid-induced bone loss if given to patients who 
were osteopenia. 
IX 
Bahasa Malaysia Version 
Pengenalan 
Pengunaan rawatan glucocorticoid yang berpanjangan boleh menyebabkan kekurangan 
kepaduan tulang dan meningkatkan risiko patah tulang. Namun demikian, gejala ini 
boleh di atasi atau di kurangkan jika langkah-Iangkah pencegahan di mulakan dari 
peringkat awal. Calcitriol (1.25-dyhydroxyvitamin D3) dan kalsium suplimentasi adalah 
satu rawatan yang wajar untuk mengurangkan kehilangan padu tulang tetapi ia tidak di 
lakukan secara berleluasa di peringkat tempatan. 
Objektif: 
Objektif utama kajian ini adalah untuk mengkaji kesan calcitriol dan kalsium 
suplimentasi dalam pencegahan osteoporosis yang di akibatkan oleh pengunaan 
glucocorticoid di kalangan pesakit SLE tempatan. Objektif-objektif lain ialah untuk 
menges an faktor-faktor yang boleh mempengaruhi kadar kehilangan padu tulang di 
kalangan pesakit SLE dan juga untuk mengkaji kesan calcitriol dan kalsium terhadap 
kehilangan padu tulang yang di sebabkan oleh glucocorticoid di antara pesakit-pesakit 
yang mempunyai padu tulang awal yang normal atau berkurangan. 
Metodologi: 
Enam puluh sembilan pesakit yang telah di rawat dengan glucocorticoid di bahagikan 
secara rambang untuk menerima calcitriol 0.25 Ilg BD atau kalsium kabomat 1.25 gm 
BD suplimentasi untuk satu tahun. BMD diukur setiap enam bulan dengan mengunakan 
dual X-ray absorptiometri (DXA) yang sama. 
x 
Tidak terdapat ciri-ciri peribadi atau risiko-risiko yang ketara di antara kedua-kedua 
kumpulan pesakit. Analisa dijalankan untuk melihat kesan suplimentasi pada BMD di 
bahagian tulang belakang (spine) dan tulang paha (femur). Analisa lanjutan di jalankan 
untuk melihat kesan suplimentasi pada BMD pesakit yang mempunyai padu tulang awal 
yang normal atau yang berkurangan 
Keputusan: 
Calcitriol adalah jauh lebih berkesan daripada kalsium dalam mencegah kehilangan 
padu tulang belakang. Purata peratus pertukaran BMD pada peringkat 6 bulan untuk 
calcitriol ialah 2.16% dan untuk kalsium ialah -0.550/0 «P=O.05). Purata peratus 
pertukaran pada peringkat satu tahun pula ialah 0.52% untuk calcitriol dan -0.32% 
untuk kalsium. Calcitriol juga dapat mencegah kehilangan padu tulang pada tulang paha 
(femur) tetapi hanya pada peringkat 6 bulan sahaja (purata peratus pertukaran ialah 
0.63%). Kalsium di dapati tidak berkesan untuk mencegah kehilangan padu tulang pada 
bahagian tulang belakang atau tulang paha. 
Pesakit yang mempunyai padu tulang asal yang berkurangan memperolehi faedah yang 
ketara dari suplimentasi calcitriol dan kalsium. Bila diberi calcitriol suplimentasi, purata 
peratus pertukaran BMD pada tulang belakang meningkat 3.620/0 pada peringkat 6 
bulan dan 1.68% pada peringkat satu tahun. Mereka yang diberi kalsium suplimentasi 
memperolehi peningkatan BMD sebanyak 0.770/0 pada peringkat enam bulan dan 1.660/0 
pada peringkat satu tahun. 
xi 
Untuk pesakit yang mempunyai padu tulang awal yang nonnal, hanya pesakit yang 
menerima suplimentasi calcitriol sahaja memperolehi peningkatan padu tulang di 
bahagian tulang belakang pada peringkat 6 bulan (purata peratus peningkatan sebanyak 
1.12%) 
Kesimpulan: 
Calcitriol suplimentasi adalah lebih berkesan dari kalsium dalam mencegah kehilangan 
padu tulang yang di sebabkan oleh glucocorticoid. Kalsium dan calcitriol suplimentasi 
juga dapat memberi perlindungan terhadap kehilangan padu tulang yang di sebabkan 




Long-term systemic glucocorticoid therapy is gIven for many steroid-responsive 
inflammatory and autoimmune illnesses and various other conditions. These include 
asthma, clrronic obstructive pulmonary disease (COPD), rheumatoid arthritis, systemic 
lupus erythematosus (SLE) and other connective tissue disease, inflammatory bowel 
disease, multiple sclerosis and in organ transplantation. 
Although the beneficial anti-inflammatory and immunosuppressive effects of 
glucocorticoid necessitate their use, adverse side effects are frequent. One of the main 
concerns is the long-term effect on bone mass and the subsequent fracture risk; hence 
the importance of early identification and implementing preventive or therapeutic 
measures. 
1.1 Definition of Osteoporosis 
The World Health Organisation (WHO) has defined osteoporosis as a condition 
characterised by low bone mass and mircoarchitectural deterioration leading to 
enhanced bone fragility and a consequent increase in fracture risk. Fractures are the 
clinical consequence of osteoporosis. The most common sites of fractures associated 
with osteoporosis are the hip, spine and wrist, but many other sites can also be involved. 
1.2 Bone mineral density (BMD) 
The introduction of BMO measurements has revolutionised the whole field of 
osteoporosis, and it is well established that bone mineral density provides the best mean 
of assessing an individual's risk of fracture (Grier SJ 1996). 
BMO can be measured using a variety of techniques and is commonly assessed at the 
hip, spine, radius and calcaneus. The most common technique for BMD assessment is 
dual X-ray absorptiometry (OXA) and results are reported as areal density in units of 
g/cm2• Areal density provides useful information relative to fracture risk; since there is 
an inverse relationship between incidence of osteoporotic fracture and areal BMO 
(Rizzoli R 1995) 
Results can also be expressed in term of the number of standard deviation (SO) below 
the average young adult bone mass (T -scores). This is the difference between the 
patient's bone mineral density and the ideal peak bone mass achieved by a young adult 
(age 20-30 years old) expressed in term of SO 
In 1994, the WHO developed a working definition of osteoporosis based on T -scores as 
shown in Table 1 (Kanis JA 1994). The WHO T-score threshold of -2.5 is commonly 
used to make a diagnosis of osteoporosis. 
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Table 1.1 Defining Osteoporosis by BMD 
Definitions based on bone mass measurement at any skeletal site (spine, hip, and 
forearm) in white women 
Degree of T-score ValueofBMD 
osteoporosis 
Normal ~-1.0 Within 1 SD of young normal adult 
Osteopenia Between -1.0 and - Between 1 and 2.5 SD below that of a young 
2.5 normal adult 
Osteoporosis ~ -2.5 2.5 SD or more below that of a young 
normal adult 
Severe osteoporosis ~ -2.5 plus had 1 or 2.5 SD or more below that of a young 
more fractures normal adult and have had 1 or more 
fractures 
BMD can also be expressed in Z score. It is the number of SD of the difference between 
the patient's bone mineral density and the mean value expected for a healthy normal 
subject matched for age, sex and race. 
Another method available for assessing BMD is by using ultrasound systems. Several 
prospective studies have shown that it may well be as effective as DXA in predicting 
risk of fracture (Hans D 1996, Bauer DC 1997). Ultrasound has the advantages of not 
using any ionising radiation, being portable, and relatively inexpensive. But so far there 
is no standard reference available for their use. The WHO criteria of the using T-score 
values interpreted from BMD measurements taken using DXA machine to express 
degree of osteoporosis and the subsequent fracture risk, cannot be automatically applied 
to measurements taken using other methods (Fogelman I 1999) 
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1.3 BMD and fracture risk 
A large number of studies have shown that BMD measurements can provide a good 
assessment of fracture risk. Every reduction of 1 SD in bone density equating to roughly 
2-2.5 folds increase in the likelihood of fractures (Marshall D 1996, Fogelman I 1999). 
However, they are less good at identifying specific individual who will go on to have 
fractures 
The relationship between BMD and fracture risk is commonly reported as relative risk 
per standard deviation decrease (RRlSD), which is the increase in risk associated with a 
decrease in BMD of 1 SD 
Eddy and colleagues as part of a comprehensive survey summarises the RRlSD for 
various commonly affected sites. (Table 1.2) (Eddy D 1998, Dennis MB 2000). 
Table 1.2 Showing the relative risk increase in fracture risk per standard 
deviation decrease in the measurement at the three major sites 
Measurement Site 
Fracture site Forearm Lumbar spine Femoral neck 
Wrist 1.8 1.6 1.6 
Vertebrae 1.6 2.0 1.9 
Hip 1.6 1.3 2.6 * 
* For every 1 SD decrease in hip BMD the Increase risk of hip fracture is about 2.6 
times 
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1.4 Glucocorticoids and bone metabolism 
The mechanisms of the effect glucocorticoids on bone metabolism have not been 
completely elucidated, but it is currently believed that glucocorticoids accelerate bone 
loss in several ways (Reid IR 1998). With prolonged administration, decreased bone 
formation appeared to be the most important mechanism leading to bone loss 
(Stevenson 1998, Pearce G 1998). 
Glucocorticoids exert a direct effect on skeletal development by increasing osteoclast-
mediated bone resorption and decreasing osteoblast-mediated bone formation (Chyun 
1984). Interference with both the birth and death cycle of bone cells reduces the total 
number of cells. An increase in osteoblast and osteocyte apoptosis also has been 
documented in animals and humans with glucocorticoid-induced osteoporosis 
(Weinstein RS 2000). In a recent in-vitro study by Smith and associates, dexamethasone 
was specifically shown to induce premature attenuation of osteoblast cell cycle (Smith E 
2000). 
Glucocorticoids have also been associated with decrease calcium absorption in the 
intestine (Lane JM 1996) thereby causing secondary hyperparathyroidism. They also 
increase urinary calcium excretion. 
Glucocorticoids can also induce hypogonadism either by suppressing gonadotrophin 
secretion or by interfering directly with sex hormone production (ACR Task Force 
1996, Sambrook PN 1988, MacAdam MR 1986). Thus they reduce the production of 
oestrogen in women and testosterone in men. Long-term glucocorticoid use may also 
contribute to muscle atrophy and progressive loss of muscle strength. 
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They however do not modify vitamin D metabolism (Reid lR 1997, Seeman E 1980, 
Hahn TJ 1981). All the above changes have subsequent effects on bone formation and 
may therefore increase fracture risk (Ziegler R 1998) 
1.5 Effect of long-term glucocorticoid use on bone 
Osteoporosis is a loss of bone mass caused by imbalance between bone resorption and 
bone formation. Unlike the more common age- and gender-related types of osteoporosis, 
glucocorticoid-induced osteoporosis can occurs at any age and even in children. Both 
male and female on prolong glucocorticoid therapy lose bone at similar rates (Lenore B 
1997). 
Until recently, it is believed that low doses of glucocorticoid (equivalent of less than 10 
mg per day prednisolone) had no significant effect on BMD. However with the help of 
more sophisticated densitometry machines that enable measurements of smaller changes 
in bone mass; recent studies have suggested that even doses between 5-10 mg of 
prednisolone per day can induce a slow decline in BMD (Lenore B 1997). 
The skeletal effects of glucocorticoid appear to be both dose and duration dependent. 
A daily prednisolone dose of more than or equal to 7.5 mg will result in significant bone 
loss and increase fracture risk (Lenore B 1997). The accumulative dose also affects the 
severity of bone loss. It is not known whether there is a threshold dose of glucocorticoid 
below which osteopenia does not occur. Alternate-day glucocorticoid regimens also 
have not been shown to produce less bone loss than daily regimens (Reid IR 1997). 
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Systemic administration of glucocorticoids has the most prominent influence on bone 
metabolism. Topical preparations have substantially less influence but there are still 
clinically evident adverse effects (Ebeling PR 1998). Even inhaled steroids have been 
shown to increase bone loss (Lenore B 1997, IP M 1994). 
It is now generally accepted that patients taking chronic systemic glucocorticoid therapy 
(the equivalent of more than or equal to 7.5 mg daily of prednisolone for more than six 
month) will develop low bone mineral density and eventually frank osteoporosis 
(Skolnick 1997). 
Many cross-sectional studies had been carried out to see the effect of oral glucocorticoid 
therapy in bone mineral density reduction and the subsequent increase fracture risk. 
They showed that the fracture rates in patients taking long-term glucocorticoid treatment 
are increased by two to five times (Lenore B 1997). Dr. Reid maintained that as many as 
one third of patients will develop fractures within 5-10 years of glucocorticoid use (Reid 
IR 2000, Reid IR 1997) 
There is only a few longitudinal research data available on the effect of glucocorticoid-
induced osteoporosis. At the recent World Congress on Osteoporosis 2000, Steinbuch 
and colleagues presented data from a prospective longitudinal study, exploring the risk 
of fracture associated with oral glucocorticoid therapy. In this study, 17,957 patients on 
long-tenn oral glucocorticoids during a 24-month capture period were followed. A 
control group consisted of patients whom are not on corticosteroid treatment. This 
cohort represented approximately 33,000 person-years of observation for each group. 
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The median prednisolone or equivalent intake for patients in the study was 4.8 mg daily. 
Significantly increased rates of hip and vertebral fractures were detected among patients 
who continuously used glucocorticoids, compared with the unexposed group. Combined 
duration of exposure and pattern of glucocorticoid use showed a 5-fold increased risk of 
hip fracture and a 5.9-fold increased risk of vertebral fracture for continuous 
glucocorticoid users, compared with the unexposed group. Wrist fracture risk was not 
increased in the glucocorticoid users. The conclusion was glucocorticoid treatment has a 
rapid deleterious effect of on trabecular rich bone (Steinbuch M 2000) 
Since glucocorticoids affect trabecular bone (spine and ribs) more than cortical bone 
(femoral neck), patients who are on long-term glucocorticoid therapy are at particularly 
increased risk for vertebral fractures (Lenore B 1997, Reid IR 1997). 
Most glucocorticoid-induced bone loss occurs at the beginning of treatment especially 
during the first 6 to 12 months (Sambrook 1993), where as much as 30% of bone can be 
lost (Reid IR 1997). The bone loss will continue, for as long as the patient is on 
glucocorticoid therapy but at a slower rate (Eastell R 1998). It has been noted that serum 
osteocalcin, a marker of bone formation, was reduced within a week of initiation of 
glucocorticoid therapy and remained suppressed as long as therapy continued (Adachi 
1996). 
By using Dual Photon X-ray Absorptiometry (DEXA), the decrease in lumbar spine 
BMD in steroid treated patients has been reported to be as high as 40% (Reid IR 1992). 
The rate of BMD reduction at the spine during the first year of steroid treatment 
averages about 8% but individual reduction in BMD may range from no reduction to 
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15% per year (Sambrook PN 1994). This implies that the individual at risk for steroid 
induced bone loss is sUbjected to significant variation, probably due to multifactorial 
nature of steroid induced osteoporosis. While steroid therapy in some patients may not 
affect bone turnover, the same treatment in others may result in significant bone loss 
(Spector TD 1993). 
Discontinuation of steroids will usually results in restoration of BMD to pre-treatment 
levels in the same period during the bone loss occur (Laan 1993). 
1.6. Risk factors influencing BMD 
1.6.1. Calcium intake 
Daily calcium intake seems to playa pivotal role especially in Asians patients, 
whose daily calcium intake is usually lower than in western popUlations. As 
steroid induces a negative calcium balance, a low calcium intake is a strong risk 
factor for increase bone turnover and subsequent bone calcium deprivation. 
1.6.2. Fracture prevalence 
Patients who have already sustained a minimal trauma fracture are at higher risk 
to be affected by steroid therapy. 
1.6.3. Age, sex and menstrual status 
Women are at higher risk for osteoporosis. Post-menopausal women (not on 
HRT) and older patients (> 65 years) are more vulnerable to steroids than the 
pre-menopausal women and younger patients. Premature menopausal is also an 
important risk factor associated with increased steroid-induced bone loss. 
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1.6.4. Genetics 
Genetics account for a high proportion of variance in BMD, so patients with 
family history of minimal trauma fractures may also at risk of getting accelerated 
bone loss once they start taking steroid therapy. 
1.6.5. Steroid dosage 
Steroid effects on bone are dose and duration dependent. 
1.6.6. Underlying disease 
The associated underlying diseases are also an independent risk factor for 
reduced bone mass. Examples are lactose intolerance, hypogonadism, 
endogenous or exogenous hyperthyroidism, mUltiple myeloma and 
hypercortisolism (Prakash UBS 2000). Rheumatoid arthritis is independently 
associated with reduced bone mass (Naganathan 2000). 
1.6.7. Small body built and reduced body weight (low body mass index) are also risk 
factors for osteoporosis 
1.6.8. Excessive alcohol intake more than 3 oz /day (alcohol IS an osteoblast 
suppressive agent) and heavy smoking are independent risk factors for 
developing osteoporosis. 
1.6.9. Others include lack of weight-bearing exercise and lack of sun exposure 
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1.7. Glucocorticoid-induced osteoporosis in Asians 
Many studies have been done on glucocorticoid-induced osteoporosis in Caucasians but 
little is known about steroid associated bone loss in Asians. Eastern populations differ 
from Caucasians in many aspects. Even though the daily calcium intake of Chinese is 
lower than that of Caucasians, the intestinal fractional calcium absorption of Chinese 
postmenopausal women seems more efficient than their Caucasian counterparts (Woo J 
1998, Kung A W 1998). 
Asians generally has lower BMD than Caucasians because they have lower body weight 
and height. But despite the lower calcium intake and lower BMD among Asians, the risk 
of hip fracture is approximately half of that in the western popUlations. It was said to be 
due to a better bone architecture, shorter hip axis length, and also a healthier life style 
among Asians. There is nevertheless accumulating evidence that Asians are also 
affected from glucocorticoid-induced osteoporosis. A study published in 1998 noted that 
the prevalence of osteoporosis among Chinese pre-menopausal women with SLE in 
Hong Kong was low (4-6%) compared to their Caucasians counterpart (12-18%) (Li Ek 
1998) 
1.8. Effect of osteoporosis and fracture 
The risk of fracture that was associated with osteoporosis is a matter of concern. Bone 
fracture will result in prolong hospitalisation, time away from work, incomplete 
rehabilitation and increase immobilisation related morbidity and mortality especially in 
the elderly. All these will directly or indirectly result in high socio-economic burden. 
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Given the high socio-economic burden of bone fracture and the increasing frequency of 
steroid usage, the need for accurate identification of patients at risk for developing 
steroid-induced osteoporosis is crucial. Nevertheless, treatment and prevention of 
steroid-induced osteoporosis also need to take into account the cost and the potential 
side effects of prolong administration of supplementation and anti-resorptive agents. 
1.9 Preventive treatments for prolonged glucocorticoid users 
Fortunately it appears that continuing bone loss induced by prolonged low dose 
glucocorticoid therapy may be preventable. However identification and intervention 
must be early. 
Multiple strategies for dealing with glucocorticoid-induced osteoporosis have been 
described especially in the recent years. A lot of studies and trials have been carried out 
and many are still on going. 
1.9.1. Discontinuation of steroid therapy will definitely result in a substantial regained 
of bone density (Reid IR 1997). If not, the dosage should be maintain to the 
minimal dose sufficient to induce the anticipated therapeutic effect. 
1.9.2. General measures 
Patients on long-term steroid therapy should be advised to exercise frequently, to 
maintain their body weight, to stop smoking, to avoid excessive alcohol intake 
and to consume food products with high calcium content. 
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1.9.3. Calcium and vitamin D 
Calcium and vitamin D supplementation has been used for many years to 
prevent glucocorticoid-induced osteoporosis, with mixed results. Calcium 
supplementation decreases bone resorption but does not completely prevent bone 
loss (Sambrook P 1993). 
Steroids induce a negative balance through inhibition of intestinal calcium 
absorption. Daily supplementation with calcium would therefore be a safe, cheap 
and effective for those with low calcium intake. 
In clinical practice however, the effect of calcium supplementation is dependent 
on the population under study. Western populations with lower fractional 
calcium absorption and higher baseline calcium intake do not seem to benefit 
from increasing the daily calcium intake (Sambrook P 1993). On the contrary, 
Asians with a more efficient fractional calcium absorption and lower baseline 
calcium intake appear to respond better to calcium supplementation (Li EK 
1998) 
The use of vitamin D3 or its metabolites in the management of steroid-induced 
osteoporosis is controversial. Early studies had demonstrated that they were 
effective in reducing bone loss. 
(i) Steroid taking patients who were treated with 2 ug 10. (OR) vitamin D3 
for months in comparison to placebo treated controls showed a decrease 
in bone resorption (Braun JJ 1983). 
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(ii) Calcitriol, in a daily dose of 1 Jlg with 1000mg of calcium has been 
reported to prevent the early bone loss associated with steroid therapy. It 
prevented bone loss only in the lumbar spine but not in the proximal 
femur (Sambrook P 1993). 
(iii) Similarly, 1 Jlg of alfacalcidol daily was effective in preventing the 
decrease in BMD of patients during their first year of steroid treatment 
(Reginster JY 1999). 
(iv) Vitamin D3 in a daily dose of 500 IU plus calcium has also been reported 
to stabilise the BMD in patients already on long term steroid therapy over 
a two-year period (Buckley 1996) 
On the other hand, there were studies that could not confirm the benefit of 
vitamin D on steroid-induced bone loss. 
(i) A weekly dose of 50,000 IU of vitamin D along with 1000mg of calcium 
failed to prevent bone loss in patients having long-term steroid therapy 
over a period of 3 years (Adachi JD 1996). 
(ii) Dykman et al showed that calcitriol was no more effective than calcium 
in preventing bone loss at the radius of patients on chronic steroid 
therapy when given 0.4 Jlg calcitriol daily for 18 months 
(Dykman TR 1984). 
(iii) A recent study in Hong Kong showed that beneficial effect of calcitriol 
on BMD of premenopausal Chinese women taking chronic steroid was 
small, at least when it is instituted late in the course of steroid therapy 
(Lambrinoudaki I 2000) 
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While vitamin D appears to be relatively safe, treatment with 1 a active 
metabolites like 1,25-dihydroxyvitamin D3 (calcitriol) warrants special attention, 
as hypercalcemia or hypercalciuria can easily complicate it (Chesnut CH 1992). 
The rational of using vitamin D or its metabolites is mainly to reverse the 
decrease in intestinal calcium absorption by antagonising the effects of 
corticosteroids on gut cells and possibly to exert a direct stimulatory effect on 
osteoblast (Meunier DJ 1993). The recommended dosage of vitamin D3 is 400 to 
800 iuld. 
1.9.4. Sex hormone 
Sex hormone replacement is also effective in reducing bone loss in men or 
women with demonstrable hypogonadism. Honnone replacement therapy (HRT) 
in testosterone deficient men resulted in increases in BMD (Lane NE 1998, Reid 
I 1996). Young steroid-treated amenorrhoiec women receiving HRT showed a 
2% increase in BMD at lumbar spine over a period of 2 years, in contrast with 
controls, who lost 1.7% BMD at the same time (Kung A WC 1999). Post-
menopausal women were also reported to benefit from HRT, exhibiting a 4% 
increase in BMD at lumbar spine after one year of treatment (Hall GM 1994, 
Lukert BP 1992). Research is being currently conducted on selective oestrogen 
receptor modulators (SERM), a new class of agents with oestrogen-like activity 
on bone but devoid of the untoward effects of estrogens on breast and 
endometrium. This sound promising and we await the results (Meier CA 1998). 
15 
1.9.5. Bisphosphonates 
Bisphosphonates are analogues of pyrophosphate that bind to bone mineral and 
inhibit osteoclastic bone resorption and thus reduce bone loss (Saag KG 1998). 
A recent meta-analysis of all clinical trials conducted so far on the prevention of 
steroid-induced osteoporosis with any kind ofbisphosphonates has demonstrated 
a significant difference between actively- and placebo-treated patients of 4% in 
the mean BMD at the lumbar spine and 2.1 % at the hip (Hornik JE 1999). Two 
commonly prescribed oral bisphosphonates are etidronate and alendronate. But 
care should be taken in prescribing them to younger individual, as data on their 
effects on growing skeleton are not yet available. 
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1.9.6. Calcitonin 
Calcitonin reduced bone resorption by having a direct inhibitory action on the 
osteoclast function. The intranasal administration of calcitonin has been shown 
to be effective in preventing the early bone loss associated with steroid intake 
(Sambrook P 1993, Adachi JD 1997). Calcitonin also can stabilise the BMD of 
patients who are already on chronic steroid therapy (Luengo M 1994). Calcitonin 
preparations are however relatively expensive. This drug has not been proven 
cost effective for the long-term treatment of steroid-induced osteoporosis. 
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2 OBJECTIVES 
2.1 Primary objective 
To study the effect of calcitriol and calcium supplementation in reducing the 
severity of bone loss in local SLE patients who are on prolonged glucocorticoid 
therapy. 
2.2 Secondary objectives 
(i) To study the effect of prolonged glucocorticoid therapy on bone density profile 
and the contributory factors. 
(ii) To study the effect of calcitriol and calcium supplementation on bone loss in 
steroid treated SLE patients who have normal or osteopenic baseline BMD 
(iii) To see the pattern of bone densitometry in patients with SLE on calcitriol 
supplementation 




The study protocol was approved by the Ethical Committee of Institute Microbiology 
Research (IM:R) on January 1998 
3.1. Sample size calculation 
Sample size calculation was done using Epi-info 6.04 to detect significant change 
in BMD between the study groups. To show a difference of 4 % change in BMD of 
the two groups, a sample size of 26 patients is necessary (if possible) to give 
Confidence interval: 95% (a.: 0.05) 
Power of study: 80% (~ : 0.8) 
3.2. Selection of patients 
Consecutive SLE patients attending the Physician clinic at Hospital Ipoh in Perak from 
January 1998 were screened. Those who fulfilled the following inclusion criteria and 
were willing to participate were recruited into the study 
3.2.1 Inclusion criteria 
(i) All adult SLE patients who were on follow-up at the physician clinic 
(ii) SLE patients who were on glucocorticoid therapy and were expected to receive 
gIucocorticoids for at least one year were included. 
(iii) Patients who consented for the study 
(iv) Patients who were not on any medication to prevent of osteoporosis like 
calcium, vitamin D, calcitonin, and hormone or biphosphonate supplementation 
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Patients were excluded from the study if they had any of the following exclusion criteria 
3.2.2 Exclusion criteria 
(i) Overt clinical and X-ray evidence of fracture due to osteoporosis 
(ii) Severe hypercalcemia from any cause 
(iii) History of alcohol abuse 
(iv) Patients taking therapy or supplementation that can affect the bone metabolism 
like oral contraceptive pills, calcitonin, calcitriol, fluoride, thiazide or 
anticoagulant. 
(v) Patients on vitamins supplements especially vitamin D 
(vi) Patients who have the following associated diseases like thyrotoxicosis, diabetes 
mellitus, hepatic and gastrointestinal diseases that can cause malabsorption or 
influence bone loss 
(vii) Patients who has stopped taking steroids 
(viii) Patients who were pregnant or were planning to conceive during the next one 
year 
3.3 Study design 
3.3.1 The study was a prospective randomised controlled trial. At entry patients were 
randomised by picking closed-labelled envelops of either calcitriol 0.25 ~g BD 
or calcium carbonate 1.25 gm BD. 
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3.3.2 Screening and before randomisation 
Patients attending the SLE clinic were screened and the patient screening form filled up 
by the investigator. (Appendix I) 
Eligible patients were given an explanation on the study. Those who agreed to 
participate were given the patient information sheet (Appendix II) to read and 
subsequently given an opportunity to raise any queries or doubts. 
Informed consents were taken and signatures endorsed on the patient consent form. 
(Appendix ill a/llI b) 
Baseline biochemical tests, plain X -rays and bone densitometry of the lumbar and 
femoral were ordered. Bone densitometry of all the patients were measured by dual 
energy x-ray absorptiometry (DEXA) using the same Lunar DPXIQ 5213 machine at the 
same radio-imaging centre to ensure consistency. The BMD scans of each patient were 
analysed by the same person (the radiologist at the imaging centre) who was unaware of 
the patient's glucocorticoid dosage and treatment group. 
3.3.3. Randomisation and data collection 
On the first visit, which was approximately two weeks after screening, baseline bone 
densitometry measurement and blood investigation results were reviewed. The patients 
were then randomised to either arm of calcitriol (l,2S-Dihydroxycholecalciferol) or 
calcium carbonate by picking up close-labelled envelopes. The dose of calcitriol 
(Rocaltriol, Roche) was O.2Sug BD and calcium carbonate was 1.25gm BD. 
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Data Collection Sheets (Appendix IV) were used to fill up demographic information and 
information about risk factors for osteoporosis, duration and dosage of steroid usage. 
Dietary calcium intake and physical exercise were also assessed. Baseline investigations 
were recorded. 
3.3.4 Follow-up 
Follow-up was done at monthly interval for three months, then 2-3 monthly thereafter. 
At each follow-up the full blood count, renal and liver functions test, serum calcium and 
phosphate levels were monitored and documented into the data collection sheet. 
(Appendix IV) 
Two or more bone densitometry profiles were measured again at the end of 6 months 
and at the end of study, which was at the end of one-year study period. 
All adverse events observed or reported by the patients were recorded. 
Patients whose serum calcium were more than 2.8 mmolll with or without symptoms of 
hypercalcemia had their calcitriol or calcium carbonate dosage reduced or temporary 
withheld till the level normalised. If serum calcium persistently elevated despite the 
above measures, the patient will be withdrew from the study 
3.3.5 Compliance 
Drug compliance were monitored by tablet count at each visit 
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3.3.6. Criteria for stopping treatment during trial 
(i) Hypercalcemia that did not resolve by dose reduction or stoppage 
(ii) Take drugs that can influence the study results i.e. oral contraceptive pills, 
calcium supplements or vitamin D 
(iii) Patients own request 
3.4 Data handling and Analysis 
All answers collected on the data sheet were given numerical coding to facilitate 
processing. After coding, data and values were entered onto and stored in the computer 
using Statistical Package for the Social Sciences (SPSS 9.01) for window software. 
Appropriate statistical analysis were used: mean, median, range, standard deviation, 
standard error of means, ANOV A, paired t-test and appropriate non-parametric statistic. 
A p value of less than 0.05 was taken as the level of significance. 
3.5 Definition 
Diagnosis of SLE 
The diagnosis of SLE was made, based on fulfilling American Rheumatoid Association 
(ARA) criteria as shown as in the screening fonn Appendix I. The patients must have at 
least 4 or more out of the 11 criteria. 
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4 RESULTS 
4.1 Patients Characteristics 
Sixty-nine patients were recruited and 54 patients completed the one-year study. But 
only 51 patients were included in the end-points analysis (Efficacy study) 
Reasons for 15 withdrawals were; 
(i) Eight patients defaulted follow-up. They either missed the second or the third 
BMD measurements. 
(ii) Four patients were out of the study as they were transferred out station due to job 
commitments or education. 
(iii) One patient got pregnant 
(iv) One patient passed away due to complication of infection and septicaemia 
(v) One patient who was with the calcium arm have to be added calcitriol due to 
persistent hypocalcaemia 
Later three more patients from the above 54 patients were excluded from the outcome 
analysis due the following reasons; 
(i) One patient was found to be non-compliant to treatment and she was also given 
anticoagulation when she developed a stroke. 
(ii) One patient developed significant renal failure with creatinine levels between 
400-600 J.lmol II unrelated to calcitriol or calcium supplementation. 
(iii) Another patient developed thyrotoxicosis, so have to be excluded from the study 
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